Pieris Pharmaceuticals has merged with Palvella Therapeutics and now operates as Palvella Therapeutics (Nasdaq: PVLA). For more information about the Company and its updates, please visit www.palvellatx.com. For more information on the merger, click here: https://bit.ly/3VEProC
Pieris Pharmaceuticals
生物技术研究
Boston，Massachusetts 7,748 位关注者
Now merged with Palvella Therapeutics. Please follow @Palvella-Therapeutics to stay up to date on Corporate news.
关于我们
In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics, Inc. (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com
- 网站
-
https://www.palvellatx.com
Pieris Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boston，Massachusetts
- 类型
- 上市公司
- 创立
- 2015
- 领域
- biotechnology research
地点
Pieris Pharmaceuticals员工
动态
-
We are excited to announce that we have entered into a definitive merger agreement with Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies. This transaction represents Pieris' deep commitment to delivering value to its stockholders by preserving the future potential milestone and royalty streams from our partnered immuno-oncology bispecifics franchise for Pieris legacy stockholders through the CVRs, while also providing the opportunity for upside in an attractive, late-stage, rare disease company. With the anticipated funding and an accomplished management team, we believe Palvella is well-positioned to advance a Phase 3 clinical program with the FDA's Breakthrough, Fast Track, and Orphan Drug Therapy Designations. https://lnkd.in/d4nnjpfx